🩸 Stem Cell Research

Identifying, characterizing, and isolating stem cell populations by flow cytometry for research and clinical transplantation.

Home → Use Cases → Stem Cell Research

Table of Contents

  1. Introduction to Stem Cells in Flow Cytometry
  2. Hematopoietic Stem Cells (HSCs)
  3. CD34 Enumeration (Clinical)
  4. Mesenchymal Stem/Stromal Cells (MSCs)
  5. iPSC & ESC Characterization
  6. Cancer Stem Cells
  7. Stem Cell Sorting & Enrichment
  8. Functional Stem Cell Assays by Flow
  9. Differentiation Tracking & Lineage Analysis
  10. Troubleshooting

1. Introduction to Stem Cells in Flow Cytometry

Stem cells are defined by two cardinal properties: self-renewal (the ability to divide and produce daughter cells that retain stemness) and potency (the ability to differentiate into specialized cell types). The major categories of stem cells studied by flow cytometry include:

Flow cytometry is essential for stem cell research because stem cells are rare and reside within heterogeneous populations. Multiparameter analysis enables their precise identification, quantification, and physical isolation for downstream functional studies.

Key Concept: No single marker defines any stem cell population. Stem cell identification always requires a combination of positive and negative markers, often arranged as a hierarchical gating strategy. A cell is identified as a stem cell by what it expresses and what it lacks.

2. Hematopoietic Stem Cells (HSCs)

HSCs sit at the apex of the hematopoietic hierarchy and give rise to all blood cell types. The classical model defines a differentiation cascade:

LT-HSC → ST-HSC → MPP → CMP / CLP → committed progenitors → mature cells

Long-term HSCs (LT-HSCs) have unlimited self-renewal capacity and can reconstitute the entire blood system upon transplantation. Short-term HSCs (ST-HSCs) have limited self-renewal. Multipotent progenitors (MPPs) have lost self-renewal but retain multilineage differentiation potential.

Human HSC Markers

PopulationHuman PhenotypeMouse PhenotypeFunctional Test
LT-HSCLin− CD34+ CD38− CD45RA− CD90+ CD49f+Lin− Sca-1+ c-Kit+ (LSK) CD150+ CD48− CD34−Serial transplantation (engrafts >16 weeks)
ST-HSCLin− CD34+ CD38− CD45RA− CD90−LSK CD150+ CD48− CD34+Primary transplant engraftment (4–12 weeks)
MPPLin− CD34+ CD38− CD45RA− CD90− CD49f−LSK CD150− CD48−Multilineage colonies in vitro
CMPLin− CD34+ CD38+ CD123lo CD45RA−Lin− Sca-1− c-Kit+ CD34+ FcγRII/IIIloMyeloid colony assays
CLPLin− CD34+ CD38+ CD10+ CD45RA+Lin− IL-7Rα+ Sca-1lo c-KitloB/T/NK cell generation

The Lineage-Negative (Lin−) Gate

The Lin− gate is critical for HSC identification. A cocktail of antibodies against mature lineage markers (CD2, CD3, CD14, CD16, CD19, CD56, CD235a) is used in a single fluorescence channel (the “dump channel”). All Lin+ cells are excluded, enriching for the rare progenitor and stem cell compartment that constitutes only 1–5% of bone marrow mononuclear cells.

Side Population (SP) Assay

HSCs can be identified functionally by their ability to efflux Hoechst 33342 dye via ABCG2/BCRP transporters. When Hoechst fluorescence is visualized on a bivariate plot (Hoechst Blue vs. Hoechst Red), the SP appears as a “tail” off the main population. This population is highly enriched for HSCs. The SP assay requires careful temperature control (37°C staining) and a verapamil or fumitremorgin C control to define the SP gate.

3. CD34 Enumeration (Clinical)

CD34 enumeration is the most widely performed clinical flow cytometry test for stem cells. It determines when to harvest mobilized peripheral blood stem cells (PBSCs) for autologous or allogeneic transplantation and measures the adequacy of collected grafts.

ISHAGE Protocol

The International Society for Hematotherapy and Graft Engineering (ISHAGE) developed a standardized single-platform protocol using sequential Boolean gating:

  1. Gate CD45+ events on CD45 vs. SSC plot
  2. Gate CD34+ events from CD45+ population
  3. Backgate CD34+ to confirm they fall in the CD45 dim / SSC low region
  4. Exclude dead cells (7-AAD or DAPI)
  5. Calculate absolute count using TruCount or Flow-Count beads
SourceTypical CD34+ FrequencyCollection MethodTarget Dose
Steady-state bone marrow1–3% of MNCsBM aspiration≥2 × 106/kg
G-CSF mobilized PB0.1–1% of WBC at peakLeukapheresis≥2 × 106/kg (optimal ≥5 × 106/kg)
Cord blood0.5–2% of MNCsCollection at delivery≥1.7 × 105/kg
Plerixafor-mobilized0.5–3% of WBCLeukapheresis≥2 × 106/kg
Caution: CD34 enumeration must follow the ISHAGE gating strategy precisely. Improper gating—such as not requiring the Boolean AND of CD45dim, CD34+, and low SSC—leads to inaccurate counts that can affect clinical decisions on harvest timing or graft adequacy. Always include the backgating verification step.

4. Mesenchymal Stem/Stromal Cells (MSCs)

MSCs are multipotent cells found in bone marrow, adipose tissue, umbilical cord (Wharton’s jelly), dental pulp, and other tissues. They can differentiate into osteoblasts, chondrocytes, and adipocytes, and are widely studied for regenerative medicine and immunomodulatory therapy.

ISCT Minimum Criteria for MSC Identification

The International Society for Cellular Therapy (ISCT) established minimum criteria in 2006 that include surface marker expression:

CategoryMarkersRequired Expression
Positive (≥95%)CD73 (ecto-5′-nucleotidase)Must be positive
Positive (≥95%)CD90 (Thy-1)Must be positive
Positive (≥95%)CD105 (endoglin)Must be positive
Negative (≤2%)CD45, CD34, CD14 or CD11bMust be negative
Negative (≤2%)CD79a or CD19, HLA-DRMust be negative

Additional useful markers include CD29, CD44, CD166, and STRO-1, though these are not part of the minimum criteria. MSC identity should also be confirmed by tri-lineage differentiation assays (osteogenic, adipogenic, chondrogenic).

Tip: MSCs lose CD105 expression with extended passage number and can acquire CD34 positivity under certain culture conditions. Always assess MSC phenotype at each passage and before therapeutic use to ensure they still meet ISCT criteria.

5. iPSC & ESC Characterization

Pluripotent stem cells—both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs)—can differentiate into any cell type of the three germ layers. Flow cytometry is used to assess pluripotency marker expression, monitor reprogramming efficiency, and perform quality control.

Pluripotency Markers

TRA-1-60 and SSEA-4 are the most commonly used surface markers for identifying human pluripotent stem cells by flow cytometry. They enable live-cell sorting of pluripotent populations without requiring fixation.

Monitoring Reprogramming Efficiency

During iPSC generation from fibroblasts or PBMCs, flow cytometry tracks the progressive acquisition of pluripotency markers. Typical kinetics: SSEA-4 appears early (day 7–10), followed by TRA-1-60 (day 14–21), with full pluripotency marker acquisition by day 21–28. Reprogramming efficiency is typically reported as the percentage of TRA-1-60+ colonies or TRA-1-60+/SSEA-4+ cells.

Tip: TRA-1-60 is the most reliable single surface marker for human pluripotency. Unlike SSEA-4, which can also be expressed on some feeder cells and differentiated cell types, TRA-1-60 is highly specific to undifferentiated pluripotent cells. Use it as your primary marker for live sorting of iPSC/ESC populations.

Differentiation Tracking

As pluripotent cells differentiate, they lose TRA-1-60 and SSEA-4 expression and gain lineage-specific markers. Monitoring the loss of pluripotency markers confirms successful directed differentiation and helps identify residual undifferentiated cells that could form teratomas upon transplantation.

6. Cancer Stem Cells

The cancer stem cell (CSC) hypothesis proposes that tumors contain a subpopulation of cells with stem-like properties—self-renewal and the ability to initiate tumor growth. These cells may be responsible for tumor recurrence and therapy resistance.

Cancer TypeCSC MarkersFunctional Assay
Breast cancerCD44+/CD24−/low, ALDH+Tumor formation in NOD/SCID mice (100–500 cells)
AMLCD34+/CD38−, CD123+Engraftment in immunodeficient mice
Colon cancerCD133+ (Prominin-1), LGR5+, EpCAM+Organoid formation, xenograft
GlioblastomaCD133+, CD15+, ALDH+Neurosphere formation, intracranial transplant
Pancreatic cancerCD44+/CD24+/EpCAM+Tumor initiation in mice
Liver cancer (HCC)CD133+, CD90+, EpCAM+Serial transplantation
Important Note: The CSC concept remains controversial. Surface marker expression may reflect a cellular state (influenced by microenvironment, culture conditions, or EMT status) rather than a fixed cell identity. CD133, for example, can be re-expressed by non-stem cells under hypoxia. Functional assays (limiting dilution transplantation) remain the gold standard for validating CSC identity.

7. Stem Cell Sorting & Enrichment

Isolating viable stem cells for downstream functional studies, transplantation, or culture requires specialized sorting considerations due to the rarity and fragility of most stem cell populations.

Sorting Considerations

Enrichment Methods Compared

MACS (Magnetic Beads)

Purity: 70–95%
Speed: 108–109 cells/hour
Viability: >95%
Best for: Pre-enrichment before FACS, large-scale clinical processing

FACS Sorting

Purity: >98%
Speed: 104–105 cells/hour
Viability: 85–95%
Best for: High-purity isolation, multiparameter sorts, single-cell deposition

Immunodensity

Purity: 50–85%
Speed: 108 cells/hour
Viability: >95%
Best for: Negative selection (removing unwanted cells), no equipment needed

Tip: For rare stem cell populations (<1%), use a two-step strategy: first enrich by MACS (CD34 microbeads, EasySep) to achieve 50–80% purity, then FACS-sort the enriched fraction. This dramatically reduces sort time and improves yield compared to sorting from the unfractionated sample.

8. Functional Stem Cell Assays by Flow

Surface markers alone cannot confirm stem cell function. Several functional flow cytometry assays exploit unique metabolic or transport properties of stem cells.

ALDEFLUOR Assay (ALDH Activity)

Aldehyde dehydrogenase (ALDH) is highly active in HSCs and many CSC populations. The ALDEFLUOR assay uses BODIPY-aminoacetaldehyde (BAAA), which is converted to the fluorescent BODIPY-aminoacetate (BAA) and retained in cells with high ALDH activity. The critical control is DEAB (diethylaminobenzaldehyde), a specific ALDH inhibitor that defines the negative gate.

Side Population (SP) Assay

The SP assay exploits ABCG2/BCRP-mediated efflux of Hoechst 33342 dye. Stem cells efflux the dye efficiently, appearing as a “side population” when Hoechst fluorescence is detected simultaneously in blue (450/40 nm) and red (675LP nm) channels.

Caution: The Side Population assay is highly sensitive to Hoechst 33342 dye concentration (typically 5 μg/mL), staining time (exactly 90 minutes at 37°C), and staining temperature. Even small deviations produce dramatically different results. Always include verapamil (50 μM) or fumitremorgin C (10 μM) as the negative control—the SP gate is defined as the region that disappears with the inhibitor.

Rhodamine 123 Efflux

Similar to the SP assay, Rhodamine 123 (Rho123) efflux identifies cells with high P-glycoprotein (MDR1) activity. HSCs are Rho123-low (efficient efflux). This assay can be combined with surface markers and is simpler than the SP assay, though less specific for primitive HSCs.

9. Differentiation Tracking & Lineage Analysis

Flow cytometry monitors differentiation by tracking the progressive loss of stem cell markers and acquisition of lineage-specific markers over time.

Hematopoietic Differentiation

LineageEarly MarkersMature Markers
ErythroidCD71 (transferrin receptor), CD36CD235a (Glycophorin A), hemoglobinization
Myeloid / MonocyteCD33, CD13CD14, CD11b, CD16
GranulocyteCD33, CD13CD66b, CD16, CD15
MegakaryocyteCD41 (GPIIb)CD42b (GPIbα), CD61
B lymphocyteCD19, CD10CD20, surface Ig
T lymphocyteCD7, CD2CD3, CD4 or CD8

iPSC Directed Differentiation Monitoring

During directed differentiation of iPSCs, flow cytometry is used at key time points to assess differentiation efficiency:

10. Troubleshooting Stem Cell Flow Cytometry

ProblemPossible CauseSolution
Dim CD34 stainingWrong antibody clone; antigen damage during processing; expired reagentUse validated clone (8G12 or 581); minimize enzymatic digestion time; titrate antibody
Low viability after processingHarsh RBC lysis; excessive centrifugation; prolonged processing timeUse ACK lysis (gentler than FACS Lysing Solution); centrifuge at 300g; process within 24h
Ambiguous MSC phenotypeExtended passage; contaminating hematopoietic cells; culture-induced changesAssess at low passage (P2–P5); include CD45 negative gate; validate at each passage
Side Population not resolvedIncorrect Hoechst concentration or temperature; old dye stockUse freshly prepared 5 μg/mL Hoechst at exactly 37°C for 90 min; use fresh dye aliquot
ALDEFLUOR false positivesDEAB control not prepared properly; dead cells autofluoresceEnsure DEAB tube is prepared immediately alongside test tube; add viability dye
Cell clumping during sortDead cells releasing DNA; high cell concentrationAdd DNase I (100 U/mL); filter through 35 μm strainer; keep cells at 5–10 × 106/mL
Low CD34+ yield after sortRare population; cells lost on tube walls; sort abort rate too highPre-enrich with MACS; pre-coat tubes with FBS; check sort purity and reduce coincidence rate
Tip: When working with bone marrow or cord blood, always lyse RBCs with ammonium chloride (ACK) buffer rather than FACS Lysing Solution. Harsher lysing solutions can damage CD34+ cells, reduce their viability, and artificially lower CD34 counts. If using Ficoll density gradient separation, be aware that some HSCs pellet with the RBC fraction.